Lilly Alzheimer’s drug gets unanimous backing from FDA panel

Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly’s experimental Alzheimer’s treatment donanemab outweighed its risks, and agreed that trial data showed it was effective in patients with an early stage of the memory-robbing disease.

See the original article at: Honolulu Star-Advertiser